{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:01:45Z","timestamp":1762671705218,"version":"3.44.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ucl.2004.01.001","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:20Z","timestamp":1113821600000},"page":"331-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician"],"prefix":"10.1016","volume":"31","author":[{"given":"Celestia S","family":"Higano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ucl.2004.01.001_BIB1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate cancer","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2004.01.001_BIB2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.pcan.4500607","article-title":"The potential role of bisphosphonates in prostate cancer","volume":"5","author":"Oades","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"23","key":"10.1016\/j.ucl.2004.01.001_BIB3","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2004.01.001_BIB4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0094-0143(02)00002-2","article-title":"Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database","volume":"29","author":"Stephenson","year":"2002","journal-title":"Urol Clin North Am"},{"issue":"12","key":"10.1016\/j.ucl.2004.01.001_BIB5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/00002512-200219120-00002","article-title":"Background to and management of treatment-related bone loss in prostate cancer","volume":"19","author":"Berruti","year":"2002","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.ucl.2004.01.001_BIB6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2004.01.001_BIB7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(05)64676-9","article-title":"Hormone therapy for locally advanced prostate cancer","volume":"168","author":"Fowler","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial","volume":"79","author":"The Medical Research Council Party Prostate Cancer Working Party Investigators Group","year":"1997","journal-title":"Br J Urol"},{"issue":"17","key":"10.1016\/j.ucl.2004.01.001_BIB9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"issue":"Suppl 4","key":"10.1016\/j.ucl.2004.01.001_BIB10","first-page":"241","article-title":"Natural history of progression after PSA elevation following radical prostatecomy: update","volume":"169","author":"Partin","year":"2003","journal-title":"J Urol"},{"issue":"Suppl 2A","key":"10.1016\/j.ucl.2004.01.001_BIB11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy: monitoring and minimizing toxicity","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2004.01.001_BIB12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1078-1439(03)00143-1","article-title":"Bone loss and the evolving role of bisphosphonate therapy in prostate cancer","volume":"21","author":"Higano","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/ard.59.10.765","article-title":"Background for studies on the treatment of male osteoporosis: state of the art","volume":"59","author":"Kaufman","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ucl.2004.01.001_BIB14","series-title":"Cecil textbook of medicine","first-page":"1366","article-title":"Osteoporosis","author":"Finkelstein","year":"2000"},{"issue":"3","key":"10.1016\/j.ucl.2004.01.001_BIB15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ucl.2004.01.001_BIB16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0305-7372(03)00076-8","article-title":"Management of treatment-related osteoporosis in men with prostate cancer","volume":"29","author":"Smith","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"Suppl","key":"10.1016\/j.ucl.2004.01.001_BIB17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis","volume":"6","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ucl.2004.01.001_BIB18","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2004.01.001_BIB20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to intermittent cyclic etidronate therapy","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2004.01.001_BIB21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. A double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2004.01.001_BIB22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ucl.2004.01.001_BIB23","series-title":"Program and Proceedings of the American Society of Clinical Oncology 1999: thirty-fifth annual meeting, May 15\u201318, 1999, Atlanta, Ga","first-page":"315a","article-title":"Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS)","author":"Higano","year":"1999"},{"key":"10.1016\/j.ucl.2004.01.001_BIB24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2004.01.001_BIB25","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.ucl.2004.01.001_BIB26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2004.01.001_BIB27","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"issue":"4 Suppl 3","key":"10.1016\/j.ucl.2004.01.001_BIB28","first-page":"32","volume":"17","author":"Higano","year":"2003","journal-title":"Oncology (Huntingt)"},{"issue":"12","key":"10.1016\/j.ucl.2004.01.001_BIB29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-na\u0131\u0308ve men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2004.01.001_BIB30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","article-title":"Androgen deprivation therapy for prostate cancer results in significant loss of bone density","volume":"54","author":"Wei","year":"1999","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2004.01.001_BIB31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","article-title":"Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial","volume":"124","author":"Lips","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ucl.2004.01.001_BIB32","series-title":"Programs and abstracts of the 24th Annual Meeting of the American Society for Bone and Mineral Research, San Antonio, Texas 2002","article-title":"Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation","author":"Bruder","year":"2002"},{"key":"10.1016\/j.ucl.2004.01.001_BIB33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5694\/j.1326-5377.1997.tb126646.x","article-title":"Hip fracture in elderly men: prognostic factors and outcomes","volume":"167","author":"Diamond","year":"1997","journal-title":"Med J Aust"},{"key":"10.1016\/j.ucl.2004.01.001_BIB34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"5","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ucl.2004.01.001_BIB35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF01626602","article-title":"Age-related hip fractures in men: clinical spectrum and short-term outcomes","volume":"5","author":"Poor","year":"1995","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ucl.2004.01.001_BIB36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1532-5415.2000.tb02647.x","article-title":"Mortality and institutionalization following hip fracture","volume":"48","author":"Cree","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ucl.2004.01.001_BIB37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB38","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2004.01.001_BIB39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2004.01.001_BIB40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2004.01.001_BIB41","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","article-title":"Fracture risk following bilateral orchiectomy","volume":"169","author":"Melton","year":"2003","journal-title":"J Urol"},{"issue":"21","key":"10.1016\/j.ucl.2004.01.001_BIB42","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2004.01.001_BIB43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"year":"2003","series-title":"Physician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","key":"10.1016\/j.ucl.2004.01.001_BIB44"},{"key":"10.1016\/j.ucl.2004.01.001_BIB45","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ucl.2004.01.001_BIB46","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB47","first-page":"1244","article-title":"Diagnostic challenges in osteoporosis. Indications for bone densitometry and establishing secondary causes","volume":"47","author":"Karsh","year":"2001","journal-title":"Can Fam Physician"},{"issue":"12","key":"10.1016\/j.ucl.2004.01.001_BIB48","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","article-title":"Bone density and fracture risk in men","volume":"13","author":"Melton","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB49","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ucl.2004.01.001_BIB50","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.288.15.1889","article-title":"Clinical use of bone densitometry: scientific review","volume":"288","author":"Cummings","year":"2002","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.ucl.2004.01.001_BIB51","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/s001980070005","article-title":"Prediction of bone loss in postmenopausal women","volume":"6","author":"Stepan","year":"2000","journal-title":"Osteoporos Int"},{"issue":"Suppl","key":"10.1016\/j.ucl.2004.01.001_BIB52","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"6","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"issue":"Suppl 4A","key":"10.1016\/j.ucl.2004.01.001_BIB53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0090-4295(01)01174-8","article-title":"Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment\/orchiectomy for prostate cancer: a review and assessment of the need for more research","volume":"59","author":"Moyad","year":"2002","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.ucl.2004.01.001_BIB54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJM199302183280702","article-title":"Effect of calcium supplementation on bone loss in postmenopausal women","volume":"328","author":"Reid","year":"1993","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ucl.2004.01.001_BIB55","first-page":"3011","article-title":"Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60","volume":"85","author":"Peacock","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ucl.2004.01.001_BIB56","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/jbmr.5650111218","article-title":"Correcting calcium nutritional deficiency prevents spine fractures in elderly women","volume":"11","author":"Recker","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9343(99)80310-6","article-title":"Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial","volume":"98","author":"Reid","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.ucl.2004.01.001_BIB58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00298497","article-title":"Annual injection for vitamin D and fractures of aged bones","volume":"51","author":"Heikinheimo","year":"1992","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.1016\/j.ucl.2004.01.001_BIB59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2004.01.001_BIB60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005768-200201000-00004","article-title":"Resistance exercise and bone turnover in elderly men and women","volume":"34","author":"Vincent","year":"2002","journal-title":"Med Sci Sports Exerc"},{"issue":"10","key":"10.1016\/j.ucl.2004.01.001_BIB61","first-page":"3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2004.01.001_BIB62","unstructured":"Resistance training in the older adult. Current comment from the American College of Sports Medicine. Available at: http:\/\/www.acsm.org\/health%2Bfitness\/comments.htm. Accessed December 5, 2003."},{"issue":"9","key":"10.1016\/j.ucl.2004.01.001_BIB63","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.2003.09.534","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2004.01.001_BIB64","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ucl.2004.01.001_BIB65","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2004.01.001_BIB66","unstructured":"IDdb - the investigational drugs database; Dec 2003. Available at: http:\/\/www.iddb3.com. Accessed December 9, 2003."},{"key":"10.1016\/j.ucl.2004.01.001_BIB67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"year":"2000","series-title":"Bisphosphonates in bone disease: from the laboratory to the patient","author":"Fleish","key":"10.1016\/j.ucl.2004.01.001_BIB68"},{"year":"2003","series-title":"USP DI Drug Information for the Health Care Professional [textbook online]","key":"10.1016\/j.ucl.2004.01.001_BIB69"},{"key":"10.1016\/j.ucl.2004.01.001_BIB70","unstructured":"Drugs approved by the FDA. Drug name: boniva (ibandronate sodium). Available at: http:\/\/www.centerwatch.com\/patient\/drugs\/dru831.html. Accessed December 17, 2003."},{"key":"10.1016\/j.ucl.2004.01.001_BIB71","unstructured":"The European agency for the evaluation of medicinal products: Zometa. Available at: http:\/\/www.eudra.org\/humandocs\/Humans\/EPAR\/zometa\/zometa.htm. Accessed December 17, 2003."},{"key":"10.1016\/j.ucl.2004.01.001_BIB72","unstructured":"Europa\u2014the EU at a glance\u2014European Governments on-line. Available at: http:\/\/europa.eu.int\/abc\/governments\/index_en.htm#members. Accessed December 17, 2003."},{"key":"10.1016\/j.ucl.2004.01.001_BIB73","unstructured":"European approval for bondronat in major additional indication. Available at: http:\/\/www.roche.com\/home\/media\/med-corp\/med-corp-2003.htm. Accessed January 12, 2004."},{"issue":"10","key":"10.1016\/j.ucl.2004.01.001_BIB74","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4065\/77.10.1044","article-title":"Tolerability of once weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Greenspan","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2004.01.001_BIB75","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"issue":"1","key":"10.1016\/j.ucl.2004.01.001_BIB76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S8756-3282(00)00291-X","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.ucl.2004.01.001_BIB77","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ucl.2004.01.001_BIB79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-642-83668-8_6","article-title":"Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma","volume":"116","author":"Adami","year":"1989","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2004.01.001_BIB80","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0090-4295(88)90410-4","article-title":"Treatment of painful prostatic bone metastases with oral etidronate disodium","volume":"32","author":"Carey","year":"1988","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2004.01.001_BIB81","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.1995.tb07715.x","article-title":"Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer","volume":"76","author":"Creswall","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ucl.2004.01.001_BIB83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S8756-3282(97)00289-5","article-title":"Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton","volume":"22","author":"Pelger","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.ucl.2004.01.001_BIB84","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1464-410X.1993.tb16269.x","article-title":"Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate","volume":"72","author":"Vorreuther","year":"1993","journal-title":"Br J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB85","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0305-7372(03)00071-9","article-title":"Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment","volume":"29","author":"Eaton","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ucl.2004.01.001_BIB86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostatic carcinoma","volume":"24","author":"Elomaa","year":"1992","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"10.1016\/j.ucl.2004.01.001_BIB87","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain\u2014a double-blind, placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylm\u00e4l\u00e4","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2004.01.001_BIB88","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer","volume":"17","author":"Strang","year":"1997","journal-title":"Anticancer Res"},{"issue":"17","key":"10.1016\/j.ucl.2004.01.001_BIB89","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.ucl.2004.01.001_BIB90","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB91","series-title":"Program and Proceedings of the American Society of Clinical Oncology 2003: thirty-ninth annual meeting May 31\u2013June 3, 2003, Chicago, IL","first-page":"379","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications after the first occurrence in patients with prostate cancer and bone metastases","author":"Gleason","year":"2003"},{"key":"10.1016\/j.ucl.2004.01.001_BIB92","unstructured":"Saad F, Gleason D, Murray R, et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [abstract 1472]. In: the American Urological Association 2003 Program and Abstract book; April 26\u2013May 1, 2003, Chicago, IL. Baltimore (Maryland): American Urological Association; 2003; p. 394."},{"issue":"4","key":"10.1016\/j.ucl.2004.01.001_BIB93","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Statis"},{"issue":"6 Suppl 1","key":"10.1016\/j.ucl.2004.01.001_BIB94","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","article-title":"Efficacy of bisphosphonates in the management of skeletal complications of bone metastasis and selection of clinical endpoints","volume":"25","author":"Major","year":"2002","journal-title":"Am J Clin Oncol (CCT)"},{"key":"10.1016\/j.ucl.2004.01.001_BIB95","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB96","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB97","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB98","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.ju.0000070685.34760.5f","article-title":"Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells","volume":"170","author":"Oades","year":"2003","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2004.01.001_BIB99","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2004.01.001_BIB100","series-title":"Programs and abstracts of the 24th Annual Meeting of the American Society for Bone and Mineral Research, San Antonio, Texas 2002","article-title":"Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid","author":"Padalecki","year":"2002"},{"issue":"6","key":"10.1016\/j.ucl.2004.01.001_BIB101","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ucl.2004.01.001_BIB102","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2004.01.001_BIB103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB104","unstructured":"TROG. 03.04. A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate. Available at: http:\/\/www.swsahs.nsw.gov.au\/areaser\/cancerservices\/documents\/0304%20Radar%20Ver%201.pdf. Accessed January 19, 2004."},{"key":"10.1016\/j.ucl.2004.01.001_BIB105","unstructured":"Clinical trials\u2014ongoing studies. Available at: http:\/\/www.cecog.org\/ongoing_studies.htm. Accessed January 19, 2004."},{"issue":"8","key":"10.1016\/j.ucl.2004.01.001_BIB106","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2004.01.001_BIB107","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB108","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/01.ju.0000042162.08938.27","article-title":"Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan","volume":"169","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB109","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ju.0000096372.07687.86","article-title":"Endothelin inhibition: novel therapy for prostate cancer","volume":"170","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2004.01.001_BIB110","unstructured":"Abbot Laboratories. Abbott laboratories provide update on phase III atrasentan clinical trials in men with advanced prostate cancer. Available at: http:\/\/abbott.com\/news\/releaseonly.cfm?id=533. Accessed on January 16, 2004."},{"issue":"8","key":"10.1016\/j.ucl.2004.01.001_BIB111","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2004.01.001_BIB112","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"16","key":"10.1016\/j.ucl.2004.01.001_BIB113","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and solid tumors study group","volume":"21","author":"Rosen","year":"2002","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ucl.2004.01.001_BIB114","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2003.07.078","article-title":"Bisphosphonates for men with prostate cancer: shifting through the rubble","volume":"21","author":"Kelly","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014304000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014304000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:12:07Z","timestamp":1758805927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014304000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0094014304000199"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2004.01.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2004.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}